Advances in the treatment of hypoparathyroidism with PTH 1 –34

Hypoparathyroidism is a rare disorder of calcium metabolism which is treated with calcium and vitamin D analogs. Although conventional therapy effectively raises serum calcium, it bypasses the potent calcium reabsorption effects of PTH on the kidney which leads to hypercalciuria and an increased risk of nephrocalcinosis and renal insufficiency. Twenty-five years ago, we launched the first systematic investigation into synthetic human PTH 1 –34 replacement therapy in both adults and children. These studies led to our current understanding of the complex nature of PTH 1–34 therapy and to the challenges we still face in our pursuit of a safe and effective physiologic replacement therapy for hypoparathyroidism.

Source: Bone - September 21, 2018 Category: Orthopaedics Authors: Karen K. Winer Tags: Full Length Article Source Type: research